Circulating tumor DNA genomic profiling reveals the complicated olaparib-resistance mechanism in prostate cancer salvage therapy: A case report

BACKGROUND: The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib has displayed superior clinical effect in metastatic castration-resistant prostate cancer (mCRPC) patients with the homologous recombination repair (HRR) genes mutations. However, when a patient’s tumor tissue volume is insuffici...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Fang, Liu, Nan, Yang, Ming-Zhen, Zhang, Xiao-Tian, Luo, Hong, Zhou, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9048572/
https://www.ncbi.nlm.nih.gov/pubmed/35611209
http://dx.doi.org/10.12998/wjcc.v10.i11.3461

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9048572/
https://www.ncbi.nlm.nih.gov/pubmed/35611209
http://dx.doi.org/10.12998/wjcc.v10.i11.3461

Ejemplares similares